Merus N.V. (MRUS) Announces Proposed Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Merus N.V. Announces Proposed Public Offering of Common Shares
August 9, 2023 4:01 PM EDTUTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we and our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the launch of a proposed underwritten public offering of its common shares (the Offer Shares). All of the common shares are being offered by Merus. In addition, Merus expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the Offer Shares (the Option Shares and together with the Offer Shares, the Shares). The offering is... More
